Ninlaro (ixazomib) / Takeda - LARVOL DELTA

Ixazomib combined with daratumumab-based regimens as first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma: A real-world historical database analysis from China (ASH 2025) - P2 | "The DI-based regimens included DICd (C: cyclophosphamide; d: dexamethasone) plus vinorelbine (VDS), DId plus VDS, DId plus denosumab, DId plus venetoclax (VEN), DIPd (P: pomalidomide), DIR (R: lenalidomide), and DIRd plus VEN. Conclusion The DI-based regimen, as an initial treatment option for transplant-ineligible NDMM patients, demonstrates efficacy comparable to that observed in previous prospective randomized controlled trials (RCTs) (NCT03012880, NTR6297, ORR: 71–96%). This real-world study conducted in China further supports the promising efficacy and acceptable safety profile of the ixazomib plus daratumumab-based regimen as a first-line treatment for transplant-ineligible NDMM patients in routine clinical practice, including among elderly patients with multiple comorbidities."

Clinical • Real-world • Real-world evidence • Cardiovascular • CNS Disorders • Diabetes • Hematological Disorders • Hematological Malignancies • Hepatology • Hypertension • Metabolic Disorders • Multiple Myeloma • Nephrology • Renal Disease • Transplantation • Vascular Neurology

Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens (ASH 2025) - P2 | "Two China-specific physician's choice of therapy (CSPCT) subgroups were created by identifying patients receiving the predominant treatment regimens in China from the identified COTA cohort (CSPCT1: DVd, D-VMP, DKd, IxaDd, DRd, DPd, DRVd, DVTd; CSPCT2: daratumumab + [either carfilzomib or bortezomib or ixazomib] + any non-IMiD). In unweighted analyses vs CSPCT2, ELRA was associated with longer PFS (mPFS, 17.25 vs 4.93 months; HR, 0.55; 95% CI, 0.34-0.89; P <.05), numerically longer OS (mOS, 24.61 vs 14.95 months; HR, 0.70; 95% CI, 0.46-1.08; P =.11), and longer DOR (mDOR, NR vs 4.70 months; HR, 0.17; 95% CI, 0.07-0.41; P <.05). Conclusions Among BCMA-naive patients with RRMM who resemble those from the MM-3 trial, patients treated with ELRA have better outcomes than patients using the predominant treatment regimens available in China."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

High risk MDS in the wke of anti-BCMA CART therapy in refractory multiple myeloma. (ASH 2025) - "Case Report We present the case of a female patient diagnosed with IgG multiple myeloma in 2015, initially treated with induction chemotherapy using lenalidomide, bortezomib, and dexamethasone (RVD), followed by autologous HSCT...She subsequently progressed on a combination of daratumumab, lenalidomide, and dexamethasone. Further disease progression occurred on a regimen of ixazomib, pomalidomide, and dexamethasone. She then achieved a temporary response to carfilzomib, lenalidomide, and dexamethasone, followed by a second autologous HSCT, but relapsed again after approximately one year of maintenance therapy...While this association warrants further investigation, it emphasizes the need for ongoing observation of patients who have received CAR T-cell therapy. Future studies should aim to clarify the potential mechanistic links, including clonal evolution, selective pressures imposed by immunotherapy, and the contribution of prior cytotoxic exposures."

IO biomarker • Acute Lymphocytic Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Cardiomyopathy • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • TP53

Real-world treatment landscape after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma: An international Study (ASH 2025) - "Novel BCMA-targeted therapies, such as CAR T-cells (cilta-cel from 2nd line, ide-cel from 3rd line) and bispecific T-cell engagers (e.g., teclistamab, elranatamab from 4th line), have become new standards of care...Abbreviations: K=carfilzomib; E=elotuzumab; Pom=pomalidomide; d=dexamethasone; Isa=isatuximab; F=panobinostat; R=lenalidomide; Tec=teclistamab; X=selinexor; Elra=elranatamab; Belamaf=belantamab mafodotin; Ixa=ixazomib... This real-world study of 100 MM patients relapsing after anti-BCMA CAR T-cell treatment shows that 91% were in their 4th or 5th line of therapy. A large majority were triple-class exposed, and 52% were lenalidomide-refractory. In the absence of a clear standard of care, common treatments were identified: elotuzumab- and isatuximab-based regimens in the 3rd line; teclistamab and elotuzumab-based options in the 4th line; and teclistamab, elranatamab, and belantamab mafodotin in the 5th line."

CAR T-Cell Therapy • Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Diabetes • Dyslipidemia • Hematological Malignancies • Hypertension • Metabolic Disorders • Multiple Myeloma • Renal Disease

A single-center retrospective study of ixazomib-based regimens as maintenance therapy in newly diagnosed multiple myeloma (ASH 2025) - "Induction regimens included VRd (bortezomib-lenalidomide-dexamethasone, 57.4%), DVRd (daratumumab-bortezomib-lenalidomide-dexamethasone, 22.2%), and DVd (daratumumab-lenalidomide-dexamethasone, 9.3%). Notably, it effectively mitigates the adverse impact of high-risk genetic factors, positioning it as an emerging therapeutic option for high-risk NDMM maintenance therapy. Longer follow-up is warranted to confirm sustained survival benefits."

Retrospective data • Cardiovascular • Hematological Disorders • Hematological Malignancies • Hypertension • Multiple Myeloma • Thrombocytopenia

Preliminary analysis of a single-center study on chidamide combined with ICD regimen in bortezomib-exposed relapsed/refractory multiple myeloma patients (ASH 2025) - P2 | "Thus, we aimed to evaluate the efficacy and safety of chidamide combined with the ICD regimen (ixazomib, cyclophosphamide, dexamethasone) in RRMM patients exposed to bortezomib...All patients had received a median of 2 prior lines (range: 1–6), with 100% exposed to bortezomib and 90.9% to lenalidomide, 18.2% to ixazomib, 18.2% to carfilzomib, and 18.2% to daratumumab... Preliminary results demonstrate promising clinical efficacy and manageable safety of chidamide combined with ICD in RRMM patients double-exposed to bortezomib and lenalidomide. Further validation with larger cohorts and longer follow-up is warranted."

Clinical • Hematological Malignancies • Hepatology • Infectious Disease • Liver Failure • Multiple Myeloma • Pneumonia • Respiratory Diseases

In-class transition from bortezomib to ixazomib-based regimens in transplant-ineligible patients with newly diagnosed multiple myeloma: A retrospective, observational, real-world study conducted in China (ASH 2025) - "The most common V-based regimens included VRd (bortezomib, lenalidomide, dexamethasone, 48.6%), Vd (bortezomib, dexamethasone, 28.0%), VCd (bortezomib, cyclophosphamid, dexamethasone, 23.4%), VAd (bortezomib, Aclarubicin, dexamethasone, 11.2%), and others. This observational study involving transplant-ineligible NDMM patients in China indicates that switching from bortezomib to ixazomib-based regimens allows for extended continuous PI-based therapy, offering favorable efficacy, acceptable safety, and enhanced treatment convenience. Despite the presence of multiple comorbidities among the patient cohort, this therapeutic strategy may serve as a viable treatment option for individuals with transplant-ineligible NDMM."

Real-world • Real-world evidence • Retrospective data • Cardiovascular • CNS Disorders • Diabetes • Hematological Disorders • Hematological Malignancies • Hepatology • Hypertension • Metabolic Disorders • Multiple Myeloma • Nephrology • Renal Disease • Transplantation • Vascular Neurology

An open-label rollover study to assess the long-term safety of ixazomib (ASH 2025) - P2 | "No evidence of cumulative or long-term/late-onset toxicity was observed when ixazomib was continued as monotherapy or in combination with dexamethasone, lenalidomide, or cyclophosphamide. These data support the overall safety profile of ixazomib, indicating that ixazomib as monotherapy and ixazomib in combination remain well-tolerated in the long-term after initial treatment."

Clinical • Amyloidosis • Hematological Malignancies • Hypertension • Infectious Disease • Lymphoma • Multiple Myeloma • Pneumonia • Respiratory Diseases

Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study (ASH 2025) - "Patients achieving at least a partial response (PR) after ≥2 courses of therapy (non-ASCT cohort) or achieving at least PR after ASCT (ASCT cohort) were switched to all-oral ixazomib-based maintenance regimens: ixazomib monotherapy (3 or 4 mg orally on days 1, 8, 15 of 28-day cycles) or ixazomib (same dose) plus lenalidomide (10-25 mg orally on days 1-14 or 1-21). This multicenter real-world study supports the clinical efficacy and a manageable safety profile of ixazomib-based maintenance therapy. The efficacy observed in the sizable non-transplant cohort and ASCT cohort is particularly encouraging, which was consistent with outcomes observed in the pivotal TOURMALINE-MM3 and MM4 trials."

Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

Safety and efficacy of carfilzomib-based combinations in relapsed/refractory multiple myeloma patients in a real-world Setting : Results of a french single academic center retrospective study. (ASH 2025) - "All patients had been exposed to IMiDs (lenalidomide, pomalidomide, thalidomide), 89% to proteasome inhibitors (bortezomib, carfilzomib, ixazomib), and 64% to anti-CD38 monoclonal antibodies (daratumumab, isatuximab). Initial weekly dosing of K followed by spacing out infusions in responding patients led to better tolerance. Currently, K-based combinations also represent interesting options as bridging therapy to CAR T-cells therapies."

Real-world • Real-world evidence • Retrospective data • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Gastrointestinal Disorder • Heart Failure • Hematological Malignancies • Hypertension • Multiple Myeloma

Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma (ASH 2025) - "Maintenance regimens comprised: ixazomib monotherapy (3 or 4 mg orally, days 1, 8, 15; 28-day cycles) or combination therapy: ixazomib (same dose) + lenalidomide (10-25 mg orally, days 1-14/21) or pomalidomide (2-4 mg orally, days 1-21); oral dexamethasone use was permitted. Transitioning to ixazomib-based maintenance regimen following Dara-based regimens is a feasible and effective strategy for NDMM patients in the real world. This approach demonstrates a favorable safety profile, maintains or deepens responses, and offers enhanced convenience, supporting its utility as a sustainable long-term treatment option."

Clinical • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis (ASH 2025) - "All were refractory to daratumumab, bortezomib, cyclophosphamide, and pomalidomide; four were refractory to lenalidomide and belantamab mafodotin; one patient with t(11; 14) was refractory to venetoclax. Three relapsed after anti-BCMA academic CAR-T (HBI0101). Additional therapies included ixazomib (2), carfilzomib (1), elotuzumab (1), and melphalan (1)... Talquetamab produced deep and durable hematologic responses in heavily pretreated patients with R/R AL amyloidosis. Assessment of organ response potential was limited by irreversible organ dysfunction at baseline and short follow-up. Treatment was feasible, including in end-stage renal disease, and the safety profile was manageable without unexpected toxicities."

Clinical • Amyloidosis • Cardiovascular • Congestive Heart Failure • Dental Disorders • Heart Failure • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Nephrology • Renal Disease • Septic Shock • Thrombocytopenia • Xerostomia

A functional precision medicine clinical trial in Relapsed/Refractory multiple myeloma: Prospective study of a high throughput drug sensitivity assay on correlation of drug sensitivity scores with treatment response (ASH 2025) - P=N/A | "All patients (100%) had prior exposure to lenalidomide, 97.5% to bortezomib, 85% to carfilzomib, 82% to daratumumab, 77.5% to pomalidomide, and 12.5% BCMA CAR-T therapy...From Oncopanel2 v1, the top drugs by DSS included bortezomib (median DSS 47.7), carfilzomib (median DSS 47.3), panobinostat (median DSS 47), and romidepsin (median DSS 45.4). From Oncopanel2 v2, the top drugs by DSS were marizomib (an investigational PI, with median DSS 46.1), carfilzomib (median DSS 40.2), ixazomib (median DSS 37.2), and oprozomib (an investigational PI, with median DSS 31.6)... The use of a high throughput drug sensitivity assay was feasible among patients with relapsed/refractory MM. In our analysis of drug-specific DSS thresholds for bortezomib and Selinexor, DSS performance varied by agent, highlighting the need for drug-specific threshold optimization. In the patients who received Selinexor, there was a non-significant tendency toward higher DSS scores in responders,..."

Clinical • IO biomarker • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia • Plasmacytoma • SDC1

Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL (ASH 2025) - P2 | "This once-weekly oral approach for treatingiNHL may prove highly useful, especially in resource limited locations once generic and internationallysourced versions are available. This study suggests the potential of long term disease control through anoral, safe, and convenient treatment regimen, supporting further study of ixazomib in larger studies."

Clinical • B Cell Non-Hodgkin Lymphoma • Back Pain • Dyspepsia • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Infectious Disease • Leukopenia • Lung Cancer • Lymphoma • Musculoskeletal Pain • Neutropenia • Non-Hodgkin’s Lymphoma • Pancreatic Cancer • Peripheral Neuropathic Pain • Solid Tumor • Thrombocytopenia

Effectiveness of second-line therapies following upfront daratumumab plus bortezomib, cyclophosphamide and dexamethasone: A new benchmark (ASH 2025) - "Consolidative high dose melphalan and autologousstem cell transplant (HDM/ASCT) after achieving an optimal hematologic response to L1 (N=17) wasincluded in L1...For 2L, 19 (34%) ptsreceived a venetoclax (VEN)-based regimen including VEN monotherapy, VEN-daratumumab, VEN-pomalidomide, VEN-bortezomib or VEN-bortezomib-daratumumab...Four received HDM/ASCT, while others had various combinations of daratumumab,bortezomib, ixazomib, carfilzomib, lenalidomide, pomalidomide, cyclophosphamide, elotuzumab,dapagliflozin and bendamustine.Hematologic responses to L2 included 15 (31%) CR, 12 (25%) VGPR, 8 (17%) low dFLC PR and 13 (27%) PRor less...Data from two additional sites will be added to the dataset by09/2025. These multicenter data will serve as a benchmark for new drug approval in the non-responderand relapsed setting."

Clinical • Amyloidosis

Nationwide real-world outcomes of POEMS syndrome: Long-term impact of ASCT, maintenance therapy, and relapse strategies in Japan (ASH 2025) - "Maintenance therapy was planned for 13 patients(12.1%), starting at a median of 131 days post-ASCT (range: 39–406) and continuing up to 3429 days.Regimens included IMiDs (n=8), PI-based regimens (n=3), melphalan/dexamethasone (n=3), ixazomib(n=1), and radiation therapy (RT, n=1)...Relapse treatments were diverse and increasinglyincluded novel agents like daratumumab, reflecting a shift toward individualized and immunotherapy-based approaches...However, secondary malignancies and infections remainsignificant concerns and call for careful surveillance and supportive care. Future research should focuson global analyses and prospective studies to validate optimal post-transplant strategies and improvelong-term outcomes in POEMS syndrome."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Rare Diseases

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study (ASH 2025) - "This is one of the first studies showing the safety and efficacy of non-IMID baseddaratumumab-combination induction therapies with in-class transition of bortezomib to ixazomib (ArmB) yielding higher response rates post-induction and post-transplant without compromising on thesafety. This translated to PFS and OS benefit as well with no survival events for Arm B with more than 60month follow up."

Clinical • P2 data • Esophageal Adenocarcinoma • Esophageal Cancer • Genito-urinary Cancer • Hematological Malignancies • Multiple Myeloma • Prostate Cancer • Solid Tumor

Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens. (ASH 2025) - "Chemotherapy was used as induction regimen prior to ASCT in 162 patients (68.1%), while 76 patients(31.9%) received induction with novel agents: 26 (10.9%) received bortezomib-dexamethasone (VD), 22(9.2%) bortezomib-thalidomide-dexamethasone (VTD), 17 (7.1%) thalidomide-dexamethasone (TD), 5(2.1%) bortezomib-lenalidomide-dexamethasone (VRD), 3 (1.3%) bortezomib, cyclophosphamide, anddexamethasone (VCD), and 3 (1.3%) other regimens...The most frequently used conditioning regimen was melphalan 200 mg/m2 (78.1%), followed bymelphalan plus total body irradiation (12.2%) and melphalan plus busulphan (8.0%)...Only 83 patients (34.8%) received maintenance therapy, ofwhom 61 patients (73.5%) received only interferon alone or combined with steroids, 8 (9.6%) thalidomide,6 (7.2%) thalidomide plus bortezomib, 5 (6.0%) lenalidomide plus dexamethasone, 1 (1.2%) thalidomideplus dexamethasone, 1 (1.2%) ixazomib and 1 (1.2) bortezomib plus dexamethasone... In our experience, 12% of..."

Clinical • Hematological Malignancies • Multiple Myeloma • Transplantation

Lessons learned from the clinical trial portfolio of ixazomib in multiple myeloma: A systematic review and meta-analysis (ASH 2025) - "In the only trial of ixazomib that led to FDA approval for a specific label, the TOURMALINE-MM1 trial, astatistically significant improvement in progression-free survival (PFS) was seen for ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in relapsed/refractory MM, butno overall survival (OS) improvement. A comprehensive review of ixazomib's clinical trial portfolio reveals that across 87 uniquetrials over 16 years, no study has demonstrated an OS benefit, despite substantially increased toxicity.The majority of ixazomib RCTs with clinical endpoints were unsuccessful. A preponderance of single-armtrials utilizing other myeloma drugs in combination failed to isolate the clinical efficacy of this drug.Concerningly, an OS decrement was seen in RCTs in the maintenance setting. As a result, the clinicalvalue of ixazomib remains unclear, despite $4.6 billion in revenue, highlighting the urgent need forintentional trial design with appropriate..."

Retrospective data • Review • Hematological Malignancies • Multiple Myeloma

Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study (ASH 2025) - P4 | "Background :The DRd regimen (daratumumab/lenalidomide/dexamethasone) has become a cornerstone of therapyfor newly diagnosed multiple myeloma (NDMM)...Wehypothesized that transitioning to an all-oral IRd regimen (ixazomib/lenalidomide/dexamethasone) aftereffective DRd induction could maintain efficacy while improving tolerability and quality of life (QoL) intransplant-ineligible NDMM patients.In this prospective multicenter study (ChiCTR2400081601), we planned to enroll 60 transplant-ineligibleNDMM patients from March 2024 to August 2026 as study subjects...Sequential IRd maintenance after DRd induction demonstrates promising efficacy, with deepenedresponses and excellent tolerability in transplant-ineligible NDMM patients. Early data suggest sustaineddisease control and potential survival benefits, while the oral regimen improves convenience and QoL.These findings support IRd as a viable maintenance strategy to prolong treatment duration and optimizeoutcomes in this..."

Clinical • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • Transplantation

A randomized phase II study of daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible or deferred patients with newly diagnosed multiple myeloma: Alliance Foundation Trial 41 (AFT-41) (ASH 2025) - P2 | "The combination was generally tolerated well with manageable toxicity, despite45.6% of patients being ≥75, offering the convenience of an oral proteasome inhibitor, ixazomib, thatminimizes the risk of peripheral neuropathy for older, transplant-ineligible or deferred patients. Follow-up is ongoing to determine the benefit of maintenance with Dara-RI v. R alone in this population.Support: AFT, Celgene, Janssen, Takeda."

Clinical • P2 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • Transplantation

Patient-reported outcomes and actigraphy following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in newly diagnosed multiple myeloma (NDMM): Subgroup analysis of US MM-6 by race/ethnicity, renal function, and area income (ASH 2025) - P4 | "US MM-6(NCT03173092), a community-based phase 4 study, demonstrated the benefit of iCT from parenteral V-based induction to all-oral ixazomib/lenalidomide/dexamethasone (IRd) in facilitating long-termproteasome inhibitor-based therapy for pts with NDMM. ePRO and actigraphy data collected in US MM-6 indicate that long-term treatment with all-oral IRd has minimal impact on health-related QoL or pt activity/sleep, including in pt subgroups typicallyunderrepresented in clinical trials. ePRO collection in pts appears highly feasible according to the averagecompliance observed. For all ePRO outcomes, considering the relatively small sample sizes, whichdecreased over time, results for later cycles and subgroups should be interpreted with caution."

Clinical • Patient reported outcomes • Hematological Malignancies • Multiple Myeloma • Renal Disease

Daratumumab-based quadruplet therapy in functional high-risk relapse/refractory multiple myeloma patients induces changes associated with CD8 T cell signaling, activation and expansion (ASH 2025) - P1/2 | "fHRMM patients with no discernibleactivating mutations and who had received 1-3 prior therapies (exposed to at least one proteasomeinhibitor and an IMiD) were given a combination of daratumumab (D), ixazomib (I), pomalidomide (P) anddexamethasone (d) (D-IPd) quadruplet therapy. These preliminary analyses of D-IPd quadruplet therapy of RRMM indicate that paired single cell RNA andTCR sequencing of BM T cells suggests a selective expansion of clonotypic CD8+ T cells. When consideringpatient response, the only PD patient profiled in this study maintained an exhaustive signature (LAG3,PDCD1) in multiple T cell compartments at BL. The differential expression of the receptor ligand pairsafter treatment between different clinical response groups suggests an altered TME response that mayinform future therapeutic stratification."

Clinical • IO biomarker • Hematological Malignancies • Multiple Myeloma • CD14 • CD8 • IFNG • LAG3 • LGALS9 • PD-1 • SDC1

IFN-α potentiates daratumumab response in multiple myeloma: A commpass study (ASH 2025) - "The modern standardof care for MM comprises a triplet of an immunomodulator (lenalidomide or pomalidomide), aproteasome inhibitor (bortezomib, carfilzomib, or ixazomib), and a glucocorticoid (dexamethasone). Here we demonstrate IFN-α may provide anestablished, FDA approved adjuvant for amplifying daratumumab efficacy. Our results warrant furtherinvestigation into the specific mechanisms of cytotoxicity induced by combination therapy as well as theoptimal treatment window for IFN-α-dependent reprogramming of CD38low clones."

IO biomarker • Hematological Malignancies • Multiple Myeloma • IFNA1 • IFNB1 • IFNG • STAT1

Quality of life in multiple myeloma: A scoping review (ASH 2025) - "Parenteral treatments for NDMM includeddaratumumab (dara) –bortezomib–melphalan–prednisone (D-VMP), bortezomib–melphalan–prednisone(VMP), carfilzomib (K), and intravenous/subcutaneous daratumumab monotherapy or combinationregimens. Oral treatments comprised ixazomib–dexamethasone with or without cyclophosphamide(ICd/Id), melphalan–prednisone–lenalidomide (MPR), and melphalan–prednisone–thalidomide(MPT)...The PI /IMiDs±others group showed a wide and variable range of changes, from -9.85 to12.8 (0–6 months), -2.99 to 4.35 (6–12 months), -6 to 1.95 (12–24 months), and -12.6 to 3.09 (>24 months).Two observational studies [PI/IMiDs regimens, V-dexamethasone (d), Rd, and Pomalidomide-d] showed astable but declined trend with -8.5 to -4.3 (6-12 months).ConclusionIn TIE NDMM, novel agents showed consistent trends of QoL improvement during induction, with oralregimens offering more stable outcomes during maintenance...While RRMM patients demonstrate poorer QoL score..."

HEOR • Review • Hematological Malignancies • Multiple Myeloma